# Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.

> **NCT05771012** · NA · COMPLETED · sponsor: **Farwaniya Hospital** · enrollment: 42 (actual)

## Conditions studied

- Management of Punctal Stenosis

## Interventions

- **DRUG:** 0.05% cyclosporin (Restasis®, Allergan Inc)
- **DEVICE:** mini-monoka stent

## Key facts

- **NCT ID:** NCT05771012
- **Lead sponsor:** Farwaniya Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05771012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05771012, "Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05771012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*